Synergistic effect of norepinephrine transporter blockade and α-2 antagonism on blood pressure in autonomic failure

Hypertension

Volumn 59, Issue 3, 2012, Pages 650-656

  Okamoto, Luis E ^a,b   Shibao, Cyndya ^a,b   Gamboa, Alfredo ^a,b   Choi, Leena ^b   Diedrich, André ^a,b,c   Raj, Satish R ^a,b   Black, Bonnie K ^a,b   Robertson, David ^a,b   Biaggioni, Italo ^a,b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VANDERBILT UNIVERSITY   (United States)

Author keywords

atomoxetine; autonomic failure; dysautonomia; orthostatic hypotension; orthostatic tolerance; yohimbine

Indexed keywords

ATOMOXETINE; PLACEBO; YOHIMBINE;

ADULT; ARTICLE; AUTONOMIC DYSFUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG POTENTIATION; FEMALE; HUMAN; MALE; ORTHOSTATIC INTOLERANCE; PRESSOR RESPONSE; PRIORITY JOURNAL; SEAT; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; STANDING; SYMPATHETIC TONE; SYSTOLIC BLOOD PRESSURE;

ADRENERGIC ALPHA-2 RECEPTOR ANTAGONISTS; ADRENERGIC UPTAKE INHIBITORS; AGED; BLOOD PRESSURE; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; POSTURAL BALANCE; PROPYLAMINES; PROSPECTIVE STUDIES; SHY-DRAGER SYNDROME; SINGLE-BLIND METHOD; TREATMENT OUTCOME; YOHIMBINE;

EID: 84857634531     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.111.184812     Document Type: Article

References (34)

1. Shibao C, Okamoto L, Biaggioni I. Pharmacotherapy of autonomic failure. Pharmacol Ther. Epub ahead of print June 8, 2011.
2. + -Fluorohydrocortisone in the treatment of postural hypotension. Acta Med Scand. 1966;179:293-299.
3. Low PA, Gilden JL, Freeman R, Sheng KN, McElligott MA. Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension: a randomized, double-blind multicenter study-Midodrine study group. JAMA. 1997;277:1046-1051. (Pubitemid 27147542)
4. Jordan J, Shannon JR, Black BK, Lance RH, Squillante MD, Costa F, Robertson D. N(n)-nicotinic blockade as an acute human model of autonomic failure. Hypertension. 1998;31:1178-1184. (Pubitemid 28191515)
5. +2 adrenoreceptor agonists and antagonists in the functional assessment of the sympathetic nervous system. J Clin Invest. 1986;78: 576-581. (Pubitemid 16074097)
6. Jordan J, Shannon JR, Biaggioni I, Norman R, Black BK, Robertson D. Contrasting actions of pressor agents in severe autonomic failure. Am J Med. 1998;105:116-124. (Pubitemid 28405234)
7. Shibao C, Raj SR, Gamboa A, Diedrich A, Choi L, Black BK, Robertson D, Biaggioni I. Norepinephrine transporter blockade with atomoxetine induces hypertension in patients with impaired autonomic function. Hypertension. 2007;50:47-53. (Pubitemid 46986009)
8. Grossman E, Rea RF, Hoffman A, Goldstein DS. Yohimbine increases sympathetic nerve activity and norepinephrine spillover in normal volunteers. Am J Physiol. 1991;260:R142-R147.
9. Jie K, van Brummelen P, Vermey P, Timmermans PB, van Zwieten PA. Modulation of noradrenaline release by peripheral presynaptic 2-adrenoceptors in humans. J Cardiovasc Pharmacol. 1987;9:407-413. (Pubitemid 17052965)
10. Kaufmann H. Consensus statement on the definition of orthostatic hypotension, pure autonomic failure and multiple system atrophy. Clin Auton Res. 1996;6:125-126.
11. Robertson D. Assessment of autonomic function. In: Baughman KL, Green BM, eds. Manual for House Officers. Baltimore, MD: Williams and Wilkins; 1981: 86-131.
12. Mosqueda-Garcia R. Evaluation of autonomic failure. In: Robertson D, Biaggioni I, eds. Disorders of the Autonomic Nervous System. London, United Kingdom: Harwood Academic Press; 1995:25-59.
13. Goldstein DS, Eisenhofer G, Stull R, Folio CJ, Keiser HR, Kopin IJ. Plasma dihydroxyphenylglycol and the intraneuronal disposition of norepinephrine in humans. J Clin Invest. 1988;81:213-220. (Pubitemid 18092256)
14. Kaufmann H, Malamut R, Norcliffe-Kaufmann L, Rosa K, Freeman R. The orthostatic hypotension questionnaire (OHQ): validation of a novel symptom assessment scale. Clin Auton Res. Epub ahead of print November 2, 2011.
15. Mayer AF, Schroeder C, Heusser K, Tank J, Diedrich A, Schmieder RE, Luft FC, Jordan J. Influences of norepinephrine transporter function on the distribution of sympathetic activity in humans. Hypertension. 2006; 48:120-126. (Pubitemid 44297533)
16. Esler MD, Wallin G, Dorward PK, Eisenhofer G, Westerman R, Meredith I, Lambert G, Cox HS, Jennings G. Effects of desipramine on sympathetic nerve firing and norepinephrine spillover to plasma in humans. Am J Physiol. 1991;260:R817-R823.
17. Birkenfeld AL, Schroeder C, Boschmann M, Tank J, Franke G, Luft FC, Biaggioni I, Sharma AM, Jordan J. Paradoxical effect of sibutramine on autonomic cardiovascular regulation. Circulation. 2002;106:2459-2465. (Pubitemid 35278802)
18. Eisenhofer G, Saigusa T, Esler MD, Cox HS, Angus JA, Dorward PK. Central sympathoinhibition and peripheral neuronal uptake blockade after desipramine in rabbits. Am J Physiol. 1991;260:R824-R832.
19. Tank J, Schroeder C, Diedrich A, Szczech E, Haertter S, Sharma AM, Luft FC, Jordan J. Selective impairment in sympathetic vasomotor control with norepinephrine transporter inhibition. Circulation. 2003;107: 2949-2954. (Pubitemid 36736638)
20. Stiefel G, Besag FM. Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder. Drug Saf. 2010;33:821-842.
21. Parikh SM, Diedrich A, Biaggioni I, Robertson D. The nature of the autonomic dysfunction in multiple system atrophy. J Neurol Sci. 2002; 200:1-10. (Pubitemid 34799914)
22. Sharabi Y, Eldadah B, Li ST, Dendi R, Pechnik S, Holmes C, Goldstein DS. Neuropharmacologic distinction of neurogenic orthostatic hypotension syndromes. Clin Neuropharmacol. 2006;29:97-105. (Pubitemid 44503886)
23. Sharabi Y, Imrich R, Holmes C, Pechnik S, Goldstein DS. Generalized and neurotransmitter-selective noradrenergic denervation in Parkinson's disease with orthostatic hypotension. Mov Disord. 2008;23:1725-1732.
24. Shannon JR, Jordan J, Diedrich A, Pohar B, Black BK, Robertson D, Biaggioni I. Sympathetically mediated hypertension in autonomic failure. Circulation. 2000;101:2710-2715. (Pubitemid 30390574)
25. Onrot J, Goldberg MR, Biaggioni I, Wiley RG, Hollister AS, Robertson D. Oral yohimbine in human autonomic failure. Neurology. 1987;37: 215-220. (Pubitemid 17015493)
26. Robertson D, Goldberg MR, Onrot J, Hollister AS, Wiley R, Thompson JG Jr, Robertson RM. Isolated failure of autonomic noradrenergic neurotransmission. Evidence for impaired -hydroxylation of dopamine. N Engl J Med. 1986;314:1494-1497. (Pubitemid 16114667)
27. Shibao C, Okamoto LE, Gamboa A, Yu C, Diedrich A, Raj SR, Robertson D, Biaggioni I. Comparative efficacy of yohimbine against pyridostigmine for the treatment of orthostatic hypotension in autonomic failure. Hypertension. 2010;56:847-851.
28. Biaggioni I, Robertson RM, Robertson D. Manipulation of norepinephrine metabolism with yohimbine in the treatment of autonomic failure. J Clin Pharmacol. 1994;34:418-423. (Pubitemid 24154144)
29. Cohen MD, Finberg J, Dibner-Dunlap M, Yuih SN, Thames MD. Effects of desipramine hydrochloride on peripheral sympathetic nerve activity. Am J Physiol. 1990;258:R876-R882. (Pubitemid 20155585)
30. Lacomblez L, Bensimon G, Isnard F, Diquet B, Lecrubier Y, Puech AJ. Effect of yohimbine on blood pressure in patients with depression and orthostatic hypotension induced by clomipramine. Clin Pharmacol Ther. 1989;45:241-251. (Pubitemid 19085102)
31. Novak V, Novak P, Spies JM, Low PA. Autoregulation of cerebral blood flow in orthostatic hypotension. Stroke. 1998;29:104-111. (Pubitemid 28046950)
32. Ring BJ, Gillespie JS, Eckstein JA, Wrighton SA. Identification of the human cytochromes p450 responsible for atomoxetine metabolism. Drug Metab Dispos. 2002;30:319-323. (Pubitemid 34175024)
33. +2-adrenergic blockade with yohimbine: bimodal, epistatic influence of cytochrome p450- mediated drug metabolism. Clin Pharmacol Ther. 2004;76:139-153. (Pubitemid 39013404)
34. Sauer JM, Long AJ, Ring B, Gillespie JS, Sanburn NP, DeSante KA, Petullo D, VandenBranden MR, Jensen CB, Wrighton SA, Smith BP, Read HA, Witcher JW. Atomoxetine hydrochloride: clinical drug-drug interaction prediction and outcome. J Pharmacol Exp Ther. 2004;308: 410-418. (Pubitemid 38134198)